A theme in which order intake for hepatitis B drug efficacy studies using PXB mice remains at a high level, driven by hepatitis B research conducted by pharmaceutical companies and research institutions. It also covers periods when total order intake falls below the previous year due to weak overseas markets, despite increases in domestic orders and the accumulation of order backlog.